The NIH-Duke Master's Program in Clinical Research, established in 1998, is one of the nation's first training programs in clinical research. This program allows participants to attend formal courses in research design, research management, medical genomics, and statistical analysis at the Clinical Center by means of video-conferencing from Duke or on-site by adjunct faculty.
The program leads to a Master of Health Sciences in Clinical Research, a professional degree awarded by the Duke University School of Medicine. There is also a non-degree option for qualified students who want to pursue specific areas of interest.
Applications will be accepted through August 1, 2020.
Clinical trial guidelines have remained similar for decades despite long timelines, high costs, and frequent failures. This forum, convened by the NIH Scientific Program and Review Interest Group (SPRIG), addresses alternative strategies and models for clinical trials.
The speakers address the following questions:
- What are some potential advantages of group-randomized clinical trials?
- How can we mitigate the impact of non-adherence and professional subjects?
- How receptive is the FDA to novel trial strategies?
- Might artificial intelligence better guide future clinical trials?